Latest Content

As more pharmacies dispense GLP-1s, payment processor reviews, higher fees and account closures are emerging as an overlooked point of friction in the access channel.

Waltz Health and Fresenius Kabi will offer three biosimilars through a direct-to-payer model that bypasses traditional wholesaler and PBM rebate channels.

Eutecma's Tempaid buy pairs reusable bulk shippers with last-mile mailers as smaller, more frequent refrigerated shipments reshape demand.

HDA's Kala Shankle says a federal licensure baseline could bring real efficiency gains for wholesale distributors and 3PLs, but only if state requirements align and every stakeholder moves on the same timeline.

With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.

As patient expectations continue to evolve, brick-and-mortar pharmacy’s path forward lies in combining trusted, face-to-face care with the efficiency and convenience patients increasingly value.

Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet rising regulatory demands.

In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.

Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.

Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.

Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.

CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.

Informa's invitation-only Leadership Summit returns to CPHI Milan Oct. 6 as executives weigh sourcing, medicine security and reshoring pressure.